Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer discovery - 1 Nov 2013

Serra Violeta, Vivancos Ana, Puente Xose S, Felip Enriqueta, Silberschmidt Daniel, Caratù Ginevra, Parra Josep-Lluís, De Mattos-Arruda Leticia, Grueso Judit, Hernández-Losa Javier, Arribas Joaquín, Prudkin Ludmila, Nuciforo Paolo, Scaltriti Maurizio, Seoane Joan, Baselga José

Abstract excerpt

UNLABELLED: Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline TP53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exome
Share to Lapatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Li-Fraumeni Syndrome

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 23950206
DOI: 10.1158/2159-8290.CD-13-0132

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23950206-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.PMID 23950206Read ↗

Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].Semantic proximity Read ↗

Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.Semantic proximity Read ↗

Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.Semantic proximity Read ↗

Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.Semantic proximity Read ↗

Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.Semantic proximity Read ↗

Synchronous Lung Adenocarcinomas With Distinct EGFR Mutations In A Patient With Li-Fraumeni SyndromeSemantic proximity Read ↗

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.Semantic proximity Read ↗

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.Semantic proximity Read ↗

The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2Semantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.